Perea G, Altés A, Montoto S, López-Guillermo A, Domingo-Doménech E, Fernández-Sevilla A, Ribera J M, Grau J, Pedro C, Angel Hernández J, Estany C, Briones J, Martino R, Sureda A, Sierra J, Montserrat E
Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain.
Ann Oncol. 2005 Sep;16(9):1508-13. doi: 10.1093/annonc/mdi269. Epub 2005 Jun 6.
The International Prognostic Index (IPI), initially designed for aggressive lymphomas, is also used in follicular lymphoma (FL) and other indolent lymphomas. Two new prognostic indexes have recently been proposed for FL [the Italian Lymphoma Intergroup (ILI) Index and the Follicular Lymphoma International Prognostic Index (FLIPI)].
Three indexes, IPI [age >60 years, extranodal involvement two or more sites, elevated lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group performance status > or =2, stage > or =3], ILI (age >60 years, extranodal involvement two or more sites, elevated LDH, male sex, B symptoms, erythrocyte sedimentation rate > or =30 mm first hour) and FLIPI (age >60 years, stage > or =3, elevated LDH, nodal involvement five or more, haemoglobin level < or =12 g/dl) were calculated in 411 patients with FL.
Overall concordance between the three indexes was 54%. A total of 126 (31%) patients were included in the high-risk group according to IPI, 131 (32%) according to ILI and 157 (38%) after FLIPI application. Ten-year overall survival rates after applying the prognostic indexes (IPI, ILI and FLIPI) were, respectively: 72%, 71% and 72%, in the low-risk group; 51%, 60% and 49% in the intermediate-risk group; and 24%, 16% and 31% in the high-risk group.
In this series, all three indexes, IPI, ILI and FLIPI, were useful to classify FL patients into differentiated risk groups, although the FLIPI identified a larger proportion of high-risk patients than the IPI and ILI.
国际预后指数(IPI)最初是为侵袭性淋巴瘤设计的,也用于滤泡性淋巴瘤(FL)和其他惰性淋巴瘤。最近针对FL提出了两个新的预后指数[意大利淋巴瘤协作组(ILI)指数和滤泡性淋巴瘤国际预后指数(FLIPI)]。
计算了411例FL患者的三个指数,即IPI(年龄>60岁、结外累及两个或更多部位、乳酸脱氢酶(LDH)升高、东部肿瘤协作组体能状态>或=2、分期>或=3)、ILI(年龄>60岁、结外累及两个或更多部位、LDH升高、男性、B症状、红细胞沉降率>或=30mm/第一小时)和FLIPI(年龄>60岁、分期>或=3、LDH升高、淋巴结累及五个或更多、血红蛋白水平<或=12g/dl)。
三个指数的总体一致性为54%。根据IPI,共有126例(31%)患者被纳入高危组;根据ILI为131例(32%);应用FLIPI后为157例(38%)。应用预后指数(IPI、ILI和FLIPI)后的10年总生存率分别为:低危组72%、71%和72%;中危组51%、60%和49%;高危组24%、16%和31%。
在本系列研究中,IPI、ILI和FLIPI这三个指数均有助于将FL患者分为不同风险组,尽管FLIPI识别出的高危患者比例高于IPI和ILI。